ONC BeOne Medicines Ltd.
Company Analysis
Latest News
BeOne Medicines' third quarter 2026 revenue of $1.9B beat estimates as Brukinsa sales climbed 34%
BeOne Medicines reported robust third quarter 2026 results, driven by the continued commercial expansion of its flagship BTK inhibitor, BRUKINSA. Total revenue...
BeiGene, Ltd. Q3 2026 Earnings Preview: What Analysts Expect on November 05, 2026
BeiGene, Ltd. (now rebranded as BeOne Medicines) is expected to report Q3 2026 revenue of $1.76 billion and EPS of $2.34, with its current price of $355.84...
BeOne Medicines reports second quarter revenue of $1.7B, beating estimates on strong BRUKINSA sales and raises its full-year 2026 outlook.
BeOne Medicines reported strong second quarter results, with total revenue increasing 30% year-over-year to $1.7 billion, surpassing the consensus estimate of...
BeOne Medicines Q2 2026 Earnings Preview: What Analysts Expect on August 05, 2026
BeOne Medicines (formerly BeiGene) is projected to report Q2 2026 revenue of $1.61 billion and EPS of $1.59, with the current $316.01 share price trading well...
BeOne Medicines' first quarter revenue jumped 35% to $1.51B on strong Brukinsa sales, leading to a raised FY26 forecast.
BeOne Medicines reported first quarter 2026 revenue of $1.51 billion, up 35% year-over-year, and non-GAAP diluted EPS of $3.24 per ADS. The results...
BeOne Medicines (BeiGene, Ltd.) Q1 2026 Earnings Preview: What Analysts Expect on May 06, 2026
Analysts expect BeOne Medicines (formerly BeiGene) to report Q1 2026 revenue of $1.45 billion and earnings per share of $0.85, with the stock currently trading...
BeOne Medicines' fourth quarter revenue of $1.5B beats estimates, driven by 38% growth in flagship drug BRUKINSA.
BeOne Medicines reported fourth quarter 2025 revenue of $1.5 billion, up 33% year-over-year, and non-GAAP diluted EPS of $1.95, beating analyst estimates. For...
BeiGene, Ltd. Reports Q4 2025 Earnings on February 26, 2026
BeiGene, Ltd. is projected to report Q4 2025 revenue of approximately $1.45 billion and earnings of $1.60 per share, with the stock currently trading at...